EUVIMEDEUVIMED entdecken
Crossref

Clinical trials in hepatitis D virus: Measuring success

Ben L Da

Hepatology · 2023-06 · 77 (6) · 2147-2157

DOI: 10.1002/hep.32732 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology, online erschienen am 22.10.2022. Verfasst von Ben L Da. Beteiligte Einrichtung: Division of Hepatology, Department of Internal Medicine, Sandra Atlas Bass Center for Liver Diseases and Transplantation , Donald and Barbara Zucker …. Hauptthemen laut MEDLINE: Hepatitis D, Hepatitis D, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis D infection results in the most severe form of chronic viral hepatitis but currently lacks effective treatment options. Therapy with pegylated interferon alpha is recommended for finite treatment duration by major liver societies. Still, it is plagued by low rates of sustained virologic response (SVR) and frequent relapses even if SVR is achieved. Recently, a wave of investigational therapies has come under evaluation, including bulevirtide, lonafarnib, pegylated interferon lambda, and REP‐2139 creating excitement with this viral infection. However, there has been significant variability in the endpoints used to evaluate these therapeutics. One of the recently introduced endpoints is characterized by a decline in HDV RNA by 2 logs, with or without achieving an undetectable serum hepatitis D virus (HDV) RNA, as a marker of virologic response. Furthermore, this measure has been combined with alanine aminotransferase normalization, also known as a biochemical response, to formulate the primary endpoint of several late‐stage studies. Per recent guidance by the US Food and Drug Administration, these should be surrogate endpoints that will ultimately portend long‐term clinical benefits. These clinical benefits may include reducing the risk of progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, and mortality. However, the optimal way to measure success in HDV clinical trials remains unknown and will continue to evolve.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis DHepatitis D, ChronicHumansHepatitis Delta VirusAntiviral AgentsNeoplasm Recurrence, LocalPolyethylene GlycolsRNA

Substanzen

Antiviral AgentsPolyethylene GlycolsRNA

Autor:innen und Institutionen

  • Division of Hepatology, Department of Internal Medicine, Sandra Atlas Bass Center for Liver Diseases and Transplantation , Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health , Manhasset , New York…

Zitieren

APA

Da, B. L. (2023). Clinical trials in hepatitis D virus: Measuring success. Hepatology, 77(6), 2147-2157. https://doi.org/10.1002/hep.32732

Vancouver

Da BL. Clinical trials in hepatitis D virus: Measuring success. Hepatology. 2023;77(6):2147-2157. doi:10.1002/hep.32732

BibTeX
@article{Da2023,
  author = {Da, Ben L},
  title = {Clinical trials in hepatitis D virus: Measuring success},
  journal = {Hepatology},
  year = {2023},
  volume = {77},
  number = {6},
  pages = {2147--2157},
  doi = {10.1002/hep.32732}
}
Kostenlos starten →